Compare · ACAD vs NVO
ACAD vs NVO
Side-by-side comparison of ACADIA Pharmaceuticals Inc. (ACAD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACAD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 52.0x ACAD ($3.69B).
- Over the past year, ACAD is down 3.3% and NVO is down 43.1% - ACAD leads by 39.8 points.
- ACAD has been more active in the news (9 items in the past 4 weeks vs 7 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- ACADIA Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $21.56-0.71%
- $42.94-1.84%
- Market cap
- $3.69B
- $191.82B
- 1M return
- +0.47%
- -6.14%
- 1Y return
- -3.32%
- -43.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1985
- News (4w)
- 9
- 7
- Recent ratings
- 25
- 25
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ACAD
- Director Baker Bros. Advisors Lp was granted 37,244 shares (SEC Form 4)
- Director Harrigan Edmund converted options into 8,107 shares, increasing direct ownership by 23% to 43,148 units (SEC Form 4)
- Director Ndu Adora converted options into 8,107 shares, increasing direct ownership by 33% to 32,908 units (SEC Form 4)
- Director Daly James M converted options into 8,107 shares, increasing direct ownership by 201% to 12,148 units (SEC Form 4)
- Director Brege Laura converted options into 8,107 shares, increasing direct ownership by 54% to 23,202 units (SEC Form 4)
- Director Garofalo Elizabeth A. converted options into 8,107 shares, increasing direct ownership by 32% to 33,489 units (SEC Form 4)
- Director Poole Jonathan converted options into 2,010 shares (SEC Form 4)
- ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- PRINCIPAL ACCOUNTING OFFICER Kihara James sold $114,393 worth of shares (5,401 units at $21.18), decreasing direct ownership by 18% to 24,509 units (SEC Form 4)
- SEC Form 10-Q filed by ACADIA Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates